U.S. Patent Office Issues Guidance to Examiners on Supreme Court's Myriad Decision
14 June 2013
Today the USPTO issued guidance (PTO_Myriad_Guidelines) to Examiners on how to apply the Myriad Supreme Court decision to applications under examination. The guidance states that claims drawn “solely to naturally occurring nucleotide sequences or fragments” should be rejected for lack of eligibility under 35 U.S.C. 101. The guidance indicates that this is only a preliminary guidance memo, and that a more detailed guidance document will be issued to examiners in the future.
As noted in our earlier post, the Myriad decision has left plenty of room for nanotech patents, despite the finding that naturally occurring genes are unpatentable. The USPTO’s preliminary guidance appears in line with the decision and does not alter that general view.
Related Insights
30 August 2024
Viewpoints
FTC’s Ban on Noncompete Agreements Is Blocked
04 September 2024
Events
Navigating Intellectual Property While Building with AI
Foley Partner Eric Sophir will present on the topic of “Navigating Intellectual Property while building with AI” at the Martin Luther King Jr. Memorial Library on Wednesday, September 4, 2024, from 4:00 p.m.-5:00 p.m. EDT.
29 August 2024
Manufacturing Industry Advisor
2024 CPSC and FDA Enforcement Trends
The enforcement trends of 2023 have continued into 2024, especially with respect to the U.S. Consumer Product Safety Commission and the U.S. Food and Drug Administration.